Lexicon Pharma and Novo Nordisk Initiate Phase 1 Study for Obesity Drug LX9851

Lexicon Pharmaceuticals (LXRX) and Novo Nordisk (NVO) have initiated a Phase 1 clinical trial for the obesity drug LX9851, triggering a $10 million milestone payment to Lexicon. The study is expected to conclude in Q1 2027.

By Maham Fatima May 1, 2026 2 min read · Yahoo Finance · May 1, 2026, 09:23 UTC

Lexicon Pharma and Novo Nordisk Initiate Phase 1 Study for Obesity Drug LX9851

Tickers: $NVO

Topics: biotech clinical trials obesity drug pharma partnership

Read the full article at Yahoo Finance

More World news

Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC